IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
06 Setembro 2023 - 9:00AM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today announced William Ho, CEO and co-founder, will
participate in a fireside chat at the H.C. Wainwright 25th Annual
Global Investment Conference on Wednesday, September 13, 2023 at
2:00 p.m. ET.
The H.C. Wainwright presentation will be available live and as a
replay on IN8bio’s website at https://bit.ly/3F1WEaQ.
About IN8bioIN8bio is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of gamma-delta T cell product candidates for
solid and liquid tumors. Gamma-delta T cells are a specialized
population of T cells that possess unique properties, including the
ability to differentiate between healthy and diseased tissue.
IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and
genetically modified approaches to develop cell therapies, designed
to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase
1 clinical trials for its lead gamma-delta T cell product
candidates: INB-200 for the treatment of newly diagnosed
glioblastoma and INB-100 for the treatment of patients with
leukemia undergoing hematopoietic stem cell transplantation. IN8bio
is initiating INB-400, a company-sponsored Phase 2 clinical trial
in newly diagnosed glioblastoma following IND clearance in late
2022. IN8bio also has a broad portfolio of preclinical programs
focused on addressing hematological and other solid tumor types.
For more information about IN8bio and its programs, please visit
www.IN8bio.com.
Company Contact:IN8bio, Inc.Patrick McCall+ 1
646.600.6GDT (6438)info@IN8bio.com
Investors & Media Contact: Argot
PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024